This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only. Earnings Call, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk_0: good morning my name is melissa and i will serve as your conference up are your today at this time offered his friends are no listen only mode a brief question and answer session will follow the formal presentation if anyone should acquire operator assistance during the conference please press start zero undertow phone keypad as reminder this conference is being recorded turning me on the call today will be doctor pizza saltzman chief executive officer of immune of it and doctor frank tory executive chairperson of immune events before we begin about to remind everyone that today's conference will include certain forward looking statements within the meaning of the private securities litigation reform act of nineteen ninety five these forward looking statements include for example statements regarding the potential of efficacy and safety of a and per product candidate and i mean event expectations regarding the timing design and results of it's clinical trials including the timing of future data out an announcement a future indications the forward looking statements are not guarantees of future performance and are subject to various risks and uncertainties assumptions known or unknown which could cause actual results to differ materially from those indicated or anticipated for more information investors are encouraged to the and of them most recent quarterly report on form turn que filed with as you see on august nine two thousand twenty one now or later turn the call over to doctor peeps altman thank you dr soften you may begin
spk_1: becky melissa
spk_2: i want to take this opportunity to thank everyone for joining the call today i realize that we do not always do quarterly earnings call but because we have been more limited in our ability to interact with the best the community of last several months than two ago we wanted to take the opportunity to have a call today to highlight the results from the quarter and engage in dialogue around our go forward strategy
spk_1: i will start the discussion today with a brief recap of our financial results and close with some comments on our programs with other lighting began by briefly reviewing our financial highlights for fiscal first quarter ended june thirtieth twenty twenty one
spk_2: are the expenses
spk_1: research and development expenses were eighteen point seven million for the three months that ended june thirtieth twenty twenty one compared with six compared to sixteen point nine million for the three months that ended june thirty at twenty twenty
spk_2: the year over year increase primarily reflected higher personal related expenses and increases related to clinical activities for analyzing data and the program why data review partially offset by lower contract manufacturing costs
spk_3: today
spk_2: general and administrative expenses were eleven point two million for the three months that ended june thirtieth twenty twenty one compared to nine point seven million for the three most that ended june thirtieth twenty twenty the earlier increase was primarily due to higher personnel related expenses
spk_1: that last the net loss was thirty point five million or thirty one sense for common share with a three month that at a june thirtieth twenty twenty one compared to twenty six point seven million or thirty eight has become a chair for the three months ended june thirtieth twenty twenty net loss to the three months that ended june thirtieth twenty twenty one and twenty twenty included three point nine and four point oh million respectively related to noncash stock based compensation expense in addition to the first quarter of a result that i just briefly reviewed we announced last week a two hundred million dollar direct investment by roy that into a minimum
spk_2: i'm joined today by doctor frank forty the executive chairman of the meat of and to is also a member of right and senior leadership team frank i believe you are a unique position to put this investment into perspective which i'd like to ask you to do baby and a diploma join today on the college and be able to tread like five minutes support the company and this investment not only are they get the job and about that also representative of the more than that it's pretty as a member of reagan senior leadership team i know the rigor with which were that the best answers that and that significant that them is further evidence of migrants continued component in and commitment to meet up at both now and importantly in the future fundamentally we believe fortuna one of the unique asset and argue the mechanism invalidated with that will save two and three trials gruff numerous studies and sponsors that there's improve or caught up in multiple occasions and we have the potential and fourteen i wanted to deliver the most flexible and patient friendly dosing experience with the best form factor in the class and we've always down the class the ante up there and market exceptionally attractive
spk_4: dude a wide range of indication that the mechanism could potentially address
spk_2: not authentic been said before but if you look at the pace of new indication announcements from all the compete in the field the interesting development intensity around the mechanism is on increasing there are now for example company targeting approximately fifteen or more distinct indications with and a half year at their views with the least five of those indicators being as well the only real last several months and these indications are characterized by high on that aid with the feel outdated standard a kill off into the thing a broad spectrum of depressants and i bet you and to the opportunity to take share in a remake multiple existing markets and wealthy create new one is really remarkable
spk_4: we've now observed in the did a middle man described in june and and another analyses that forty no one is even more potent that we did we expected which opened up a path for us to be uniquely flexible are dosing and strategies to the address the myriad of diseases that to be impacted by a few around in particular the flexibility go thing and not only enables me to bet to design prob
spk_2: yeah for target the ideal level of i did use depression and a particular disease but we believe also will enable new band with like totally to regiment where changes in albumin and ldl out of normal and it's will be mostly either modest or absurd the duration during an induction pay for example in addition when you think of a single like livid elevation our ability now consider things like those those interview and ducks in a maintenance an exclusion criteria baseline live animals treatment that i live in therapy cetera and is generally bring a degree of thoughtfulness for the issue is the fourth much different now than it was one this with it
spk_1: unexpected signal first the don't think get the design elements that take advantage of work you want flexible profile from our trials in the future
spk_2: you know that said this is where keep at it moving fast with well capitalized competitors pursuing indicators aggressively area for example organics rave about a billion dollars in february two eight and a basket of their drugs and enough the different medications and they said they planned have fifteen by twenty two one five jj is like live moving aggressively poster acquisition of momentum
spk_4: and i feel with that degree in investment taking a serial and stepwise approach is not the strategy we were them thought that position the company for lot of success to sword government really designed to allow the company to move forward and on encumbered way and let the he really be aggressive with their clinical development approach you know in particular we really appreciate a unique features that anybody offers in terms of the very broad therapeutic window with it's convenient know volumes of genius injection form factor do we think of youtube and fourteen one really make a big difference for many many patients but to realize that potential a we know of you advance going to need attitude and and ambitious clinical development plan
spk_2: in some cases and youtube and have already ready to run a controlled trial and into design elements that would differentiate tuna one for the competing assets in the class in other cases admitted that will be running first in class proof of concept that is a new indications and to be a leading and a half year in which we definitely believe me to that can be and fourteen a one can be will need to execute many of these trials and parallel and that's where the rather two hundred million dollar investment really made a lot of sense to ensure we can drive long term value creation
spk_4: you know when you step back drugs with validated mechanisms very large market opportunities and transformative potential market this big to don't come around very often and with approximately five hundred seventy five million now in the balance sheet of european well equipped to focus on the executing their trial as well as expanding the do indications the right and it's incredibly excited about the prospect of work in a one and were eager to sporting events
spk_2: through this investment underwater gauge me that i also look for the personally are continuing to work closely with pete an immunity to help develop in a want to help maximize the benefits the patience and a dry peter value for our shareholders and so thanks for having me on the holiday and that are back to beat that an additional damage
spk_1: thanks frank that's a great overview before i get to the two hundred million dollar investment firm right i i'd like to discuss my senior gravest from both a strategic angle and in terms of execution
spk_2: let's start with execution
spk_1: i believe we are on track to gain alignment on a pivotal mg design with the f t a and queue for this calendar year
spk_2: in fact we have communicated with ft a regarding a meeting earlier you for to review modifications to our pivotal three study and mg
spk_1: these modifications are based on the agency that and feedback attained during our previous and a face to leading and are also based on our recently communicated program wider you
spk_2: contingent upon the ft a feedback we receive and you for we plan to initiate our study in the early part of twenty twenty two and we're very excited about how this program is shaping up
spk_1: any live with the yang getting back into the clinic will be an important catalyst for need of and especially getting the remaining opportunity we see for patients and for fourteen a one based on our understanding a patient needs and fourteen a ones potential
spk_2: i also think the strategic opportunity for forging a one is under appreciated by the market
spk_1: not surprisingly i mean events market research highlights the enthusiasm that neurologist have for the anti ft or and class generally the rapid onset of symptoms control and percentage of deeper spawners have been impressive especially given that studies reported to date have involved short term dlc recently or marketing a medical teams dug deeper with patients and with physicians who treat large populations of patients with my senior gravest this research highlight something very important specifically the patients strongly desire to avoid relapse when patients with my cd gravest relapse weakness and symptoms can occasionally get much worse very quickly
spk_2: relapse can be a crisis the patients one study control
spk_1: at the same time for this and patients do desire to minimize immunosuppression in the long run
spk_2: i think that is why an induction and maintenance approach resonates with conditions or do you know once brought therapeutic window is very well suited here our higher doses achieve the rapid and deep gg reduction need to maximize the initial clinical response that are broad therapeutic window and convenient subcutaneous dosage warm enable us to design a study that steps down i did you suppression to match patients needs without the pk pt extremes of sick with therapy on june first we disclose data regarding fourteen a ones brought their getting window and the insights gained from the comprehensive program of you
spk_1: i want to emphasize that these insights inform our enthusiasm for the potential of fourteen a one broadly not just an object
spk_2: patient needs differ by indication by severity of by stage of disease and we believe this variability his best addressed with a therapeutic option that offers a range of treated target i did you suppression levels
spk_1: the flexibility and dosing not only enabled us to design programs with the i did ideal level of i did use oppression but as frank said we believe this will also enable us to design dosage regiments were changes and albumin and ldl outside of normal limits for mostly be a short term duration during induction what we see today is that dose dependent changes in ldl are predictable and reversible
spk_2: we've also seen at the peak a pt cursor i gg differ from the pk pt curves for albumin and therefore al dia our models predicted as we go from high doses during the induction phase to more modest us and during the made it says and the albumin and ldl will generally will generally returned to values with a normal limits while agency will remain suppressed that levels that are likely to maintain a clunker response from most patients i expect or mg protocol and frankly or hook protocols and many other conditions to be unique undifferentiated in this regard
spk_1: moving on to another condition i'd also like to review our approach to paradise disease as we previously disclosed we had to prematurely terminate our face to be study afford you know on a moderate to severe ted due to our hundred dissipated program i'd look at the view
spk_2: prematurely discontinuing a study is always difficult especially for patients investigators and in this case more so as only forty one of the projected seventy seven subjects to be randomized completed the primary advocacy evaluation that we thirteen a bit over fifty percent
spk_1: consequently the question that the study was designed answer that is whether at twelve we course of fourteen one improve prop doses could not be answered with any certainty what we did observe that fourteen a once in a dose dependent manner decrease the total i g g and thyroid stimulate stimulating immunoglobulin
spk_2: as previously disclosed on review the data from the early study that that's when approximately eighty five percent of the enroll patients were assessed for proposes response at each visit it appear that that six hundred eighty milligram just and possibly the three hundred forty milligrams does that achieve a meaningful separation from placebo
spk_1: we believe that the fourteen a one induced declines in total i gg and thyroid stimulating immunoglobulin coupled with the advocacy trans observed at the early visits when most of the an old subjects were evaluated for these efficacy parameters are promising we've also been following the evolution of the market carefully of the last couple of quarters read it was a very early believe and the potential of third i did the that's an indication having design studies as early as twenty ninety initial enthusiasm was driven by an understanding that the unmet need is very high and that the addressable population was solidly in the range of other read visas might surprise people don't recall the temperate in the map face to data was originally published in the new england journal of medicine and twenty seventeen nevertheless by twenty nineteen one ronald reagan was designed to fourteen a one trials i don't think the opportunity was fully appreciated today that is certainly no longer the case as tougher to the next launches clearly validating the market opportunity
spk_2: physicians and patients are enthusiastic about medical therapy for third eye disease with decreased doppler symptoms and reduce need for surgery he benefits are great for many patients however insulin growth factor also appears to be a pretty foundational pathway across many organ systems to blocking this pathway may have consequences beyond the extra colored tissue that is the target and bar and i did this i'm aware of a recent study presented and and or twenty twenty one virtual conference that reported sixty five percent of patients receiving tempered him a map in a small piece here is experienced are allergic symptoms
spk_1: hearing impairment including deafness is also reported in the up to a label as having a greater incidents on tap or to about this compared to placebo it's early days will have to see how this all plays out in terms of clinical experience and product lately but i do think it highlights an opportunity for a product with a different mechanism of action and a potentially different benefit risk ratio another important point regarding third eye disease relates to the market potential that right at recognized a couple years back is a really understanding patient needs
spk_2: and my experience across a wide range of autoimmune conditions with high and that need physicians and patients not only appreciate that also really need medications with different mechanisms of action
spk_1: given the diversity of individual patients it's almost inevitable at some patients were song better to one mechanism and others will respond better to a different mechanism of action beyond that patients who are severely or even moderately impact and often require sequential therapy with different mechanisms of action to get close to being fully well
spk_2: bottom line i'm really excited about the opportunity for patients and for fourteen a one in ten we've also been working on getting a warm out of your him like a nuclear program started
spk_1: we found the data generated prior to the chronicle pause to be compelling albeit on a small dataset of only three patients who completed eleven or twelve weeks of therapy
spk_2: experts experts who are viewed our data with us shared with us that spontaneous improvement is uncommon in these patients after failing multiple rounds of steroids and immunosuppressant in particular i find our observation that one of the three patients experience a very strong response and maintain this response throughout the treatment period to be very encouraging
spk_1: this large improvement in hemoglobin can be achieved with very high dose steroids but very high does steroids just aren't a long term solution
spk_2: the patience and of tapering down relapsing are partially riyadh thing and then many of them are still getting intermittent blood transfusion
spk_1: that's certainly not an ideal standard care
spk_2: i said earlier that i wanted to get back to talking about the importance of romance two hundred million dollar direct investment in this is probably a good point to do that as right mentioned earlier there are fifteen indications being actively studied across the anti of and class
spk_5: that's remarkable
spk_1: people are very excited about this class and i agree with frank that the right strategy is for ambitious parallel development
spk_2: we're now well positioned to pursue the strategy
spk_1: with regard to the timeline for providing additional a place updates are just reiterate that we expect to provide a meaningful update on our mg program by the end of the year
spk_2: specifically that we've achieved alignment with the up yeah we expected to the same thing for our cat in we have programs and early twenty twenty two
spk_1: i that will be announcements of our new indications later and twenty twenty two once these are ready to go with regulatory alignment
spk_2: we also plan to hold an r a d day and the first quarter of twenty twenty two and i'm sure that would be very interesting in summary we expect a steady stream of strategic and execution updates that we believe will be very exciting for investors or later by data across a wide range of education the stream of updates and even more so the stream of progress the meat events development program because very enthused to the asked about our prospects
spk_1: with that ls the operator to open a line for questions
spk_0: thinking at this time will be conducting a question and answer session if you'd like to ask a question please press star one or your telephone keypad a confirmation tumble indicate airlines and the question can you me press start to every night to remove your question from the queue for participant using speaker equipment he may be necessary to pick up your huh since before pressing the start our first question comes from the line of robin can ask us to securities please proceed with your question
spk_6: hey guys my name thank thank you so much fucking my called a coupon for robin i'm a so the pure mentioned time to initiate clinical trials in at least two indications maybe you can talk you talk about all the fifteen indications that at the are being investigated and can you talk a little bit of of the rationale behind election of these indications anderson of convince you said that at least wanna be trials will be a pivotal trial is that beyond mg tight end way ha and then maybe a little too early to talk about it but it's fourteen or one please out the way you're expected to impaired how do you see the market evolve and pad thank you
spk_2: i showed a great set of a question there so first your first question related to our selection criteria and dumb i mentioned that there are fifteen different indications now posted in contrast i come across the entire ntsc or and class how will we select which indications were going to pursue next i think that's a pretty classic type of analysis that we're doing with the probably the two most important elements being the probability of technical success how good of a fit as the anti on max mechanism for the particular disease and question as one element and then secondly the the of on that need how much an opportunity is there to benefit patients in addition of course will consider the unique features of you know one that i discussed including the abroad therapeutic window and they're really simple subcutaneous form factor
spk_1: and them and as mother logistical factors like the clarity of regulatory and points all that goes into
spk_2: our decision making
spk_1: ultimately we want to have a lot of indication of which we have enough to to be best in class where there's already been clinical validation perhaps by another asset and then some indications where we can be first in class
spk_2: i think that's for years for your first question with regard to the statement around and and one of our indications beyond m g being pivotal that could apply to way how to add or one of the new indications are were thinking about those for indications as a group and we believe that one of them will begin with a pivotal trial and twenty twenty two and then we'll also have up to previously announced a little trial and mgs that's to pebble programs in twenty twenty two finally forgot to are it i did the that he gets it's a really really interesting market you know it's a like many of the auto antibody conditions for a long time there wasn't a good therapy there were some therapist for sure and there was good surgical therapy for patients who had extreme impact of third eye disease that they're just wasn't a good medical therapy so with the advent of new innovation and with the launch of temperature to the mob i think what physicians are experiencing is that there is a lot of unmet need in this marketplace and lot of opportunity for patients to benefit
spk_1: ever to have as of course indicated for relatively short term therapy having been studied for six months and out that she is a high degree of initial prop toasters his response which is great
spk_2: and third eye diseases not as chronic of a condition or something like my senior gravest at some patients are still impacted after their six month course of therapy and other patients relapse after the therapy is stopped so all of that makes me think that over time this market will evolve to to a situation where patients many patients will be treated sequentially with more than one mechanism of action to get them as close to normal as close to fully well as they can be and to maintain that response as long as possible
spk_7: i thank you so much
spk_8: yeah
spk_9: thank you i next question come from the line of commitment with be leaving please pretty ridiculous
spk_2: hey guys the morning thanks for taking their questions and thanks for the of this as a source in terms of fourteen a window thing are there any additional analyses that have been conducted on the previously collected data and if so when can we expect to see these analyses communicated yeah thank them for that question so we are taking the totality of data that we we have from all the patients who were just with forty one prior to the
spk_1: pause and dosing and continuously refining or models
spk_2: to give us an understanding of how dosage regimens that we haven't yet studied might perform that of he says you know the though the rationale for pick a pt modeling so yeah we're looking at a lotta different dumb potential dosage regiments and we expect those to inform our protocols going for
spk_9: word and i would expect that some you know detailed information regarding the output of our models and the design of our protocols including and he knew dosage regiments would be part of our are indeed a in the first quarter of twenty twenty two okay that makes sense i from and then i'm it sounds like you're relatively close to ah you know having a pretty good idea of the the trial designed for the pivotal and she study i guess what else would you be able to share with us
spk_2: both in terms of of details around that study and then i guess you know what the i love you what you feel i the major outstanding are propagating factors to starting that study i'm environment with the agency right right so in terms of the the protocol itself i mean i think you know as as indicated i see a lot of opportunity for an induction and made in cyber approach so reading the product all that time we ultimately achieve alignment with the up to a on two courses that depended on any final feedback they have well we'll have a will have that flavor
spk_9: the in terms of getting factors it's really just the logistics of them you know the back and forth and getting alignment with the at the a that them that we have to work you're at this point okay and then maybe i'm one less less repeat in terms of down i guess your your overall engage them with the agency across three different divisions of you can they be speak to i guess any other gating factors that you feel like are outstanding in terms of being able to restart you know the way high and paradise
spk_10: these programs
spk_1: right right
spk_2: it it's really the same an element is what i just mentioned for my the gravest obviously we have the most the data in my senior gravest and so that is some that's a good place to start having completed and and the face to meeting with the our division previously and them so that to that interaction will be will be the first one and then the interactions with the other divisions will follow and there's obviously a high
spk_9: whole host of background information that is the same for any interaction and a lot of that will be reviewed first with the agency the that interactions with the neuro division
spk_11: okay great thanks to a present guessing in the question
spk_0: yeah the random
spk_12: thinking or next question comes from line as douglas out with it seemingly seems pretty with your question
spk_13: hi good morning thanks for taking questions just your kid as you think through invitation and prioritization is there in any change for thinking and just given sort of some of the flexibility in terms of dosing and managing albumin of all the now the a levels that will be needed at you
spk_2: yeah i think the biggest like kane just as we are doing our final preparation for the june first term paul and that finalizing are ten k and that was really rooted honestly in optimizing efficacy within immunology conditions and what we kinda realize dog is that across a wide variety of immunology indications you you want to optimize advocacy by treating hard up front with induction and man minimum the patients long term immunosuppression by to bring down a little bit and say so this induction a maintenance phase is really used across a wide variety of mechanisms and indication to optimize the advocacy so i think the advocacy is always one of the most important things for any new asset we then realized that this approach was off attractive from an album and in lpl standpoint primarily because as i mentioned earlier today and previously the pick a pt models are different for a i gg and for arguments are you get
spk_1: a a much steeper
spk_2: fall of of the album an impasse as you step down the dose as or do though reduction in the i g g so that allows for a super sweet spot to be achieved for chronic dosing with a with a more mid range of those fancy that such as really good as you do reduction memory reported the sixty two
spk_1: percent median reduction i gg for the to thirty five dose while having a much more modest impact on how the men and therefore ldl were that a dose had a fifteen percent
spk_12: decrease in album and a fifteen percent increase in ldl speaking about thirty thirty five does so that's really that's really fundamentally what i think it's gonna provide a great passport and lot of indications
spk_2: it's just it's like the clappers you don't really see this being served on limit our in terms of one indications you may or may not for sale at this point i doubt because again and know in the short term when you're that adoption phase the the goal of the of the finish of as as a physician of all the patient is really to get the symptoms under control is really around advocacy there will certainly be some small percentage of patients
spk_1: two for whom i'm a medication that changes altimeter ldl even for a short term may not be appropriate but that's going to be true of have any asset will be a small percentage of patients that aren't aren't ideally suited and it'll be a large majority occasion to for whom this can be a really nice milk a nice option
spk_14: i'm maybe i'm trying to the make a point as well other than oh he's got a lot about this topic
spk_4: when i hear yet
spk_2: he might be on your side effect beaten i think the european we're we're about it in others in the the other are thinking about the money issues right and if you if you see how it manifests for example and the nib macallan ab face redesign that that has just been released by jay day
spk_4: and then it didn't change much from the protocol they wanted to go forward with other than adding an exclusion criteria for patients to had myocardial infarction unstable angina heart disease or stroke within within twelve weeks screening so clearly other companies are grappling and with in the field kind of summer gotta be shared with the at the a they could about how they go forward and will take lessons opposite from those
spk_15: and that voice
spk_0: thank you so much
spk_16: xx
spk_2: thinking or next question comes from line of sam's lucky with lifetime cabinet please proceed with caution eg morning everyone and for on the presentation just one question for me in terms of resuming development and way hi tagged are you able to discuss what the general design and size text i use my look like and then for tagged make such see data from the face to study prior to next steps
spk_1: he had a great question sam so the total billion dollar investment boy bands obviously love this lot of flexibility not thinking so we're you know we're thinking about the best way to approach both of those conditions in terms of next steps
spk_2: i'm in the context of what we've learned so far and in the context of you know what we have no want to achieve which is a a differentiated approval in those indications don't not yet able to to get more specific beyond that in terms of the the releasing the far i did these data in greater granularity
spk_17: prior to gaining alignment with the at the adult out our next trial i don't think will get out at the you know right now we have i'm a lot of information that were pouring over know confidentially was some advisers and design using it to design designer napster an next trial and baradar disease and then probably at the time that we announced that
spk_0: that is either that next rollo be good time to share more detail on but we've observed
spk_2: i have got it thanks thank you or next question comes from the line of yeah kingsmead out with doesn't home please proceed with your question
spk_18: i this is abby known for yeah thank you for taking our questions you know what specific steps would you take to mitigate the ldl issue
spk_1: in the head trial that you're starting up again or or anything that you're doing beyond potential adjustments in the dosing regimen
spk_2: and then i have a quick follow yeah thanks that evident it's the third eye diseases is a little bit unique in that it
spk_1: like the a shorter duration of therapy so this is a condition that
spk_2: may just have induction and then there with the maiden says could be off medication that's essentially the temperature the map design which makes sense in a in a condition that is somewhat self limited third eye disease resolves over a period of years versus many medical versus the other conditions which don't resolve spontaneously so i think given that the oh thing and erudite of these are likely to be have a shorter term duration then maybe that there's nothing particular that needs to be done for a leopard management even that shorter terms of scary excursions and ldl for the vast majority of patients particularly with some modest inclusion exclusion criteria changes won't really be an issue let's that we are considering you know the the kinds of things that you'd imagine and frank highlighted that briefly in his prepared march which is dosage modification or anti look at their be that like and that could play a role in third i did these programs as well some all that stuff is a things are looking at them will get finalized over the next them six months here got it and then just one quick follow up or there are indications are subsets of patients with in a particular indication across the fifteen indication that you mentioned that are currently being investigated in the as year and space know where these livid issues are not that big a deal yeah there's a there's a wide variety of call morbidities for the most of the auto antibody conditions the com morbidities are not actually that significant and that maybe because for many of the auto and about it conditions there's not as a there's not as significant above a of total body inflammatory date as there are in some of the more general autoimmune conditions
spk_19: but but certainly if you look across all fifteen you'll find you'll find some variability i think you know maybe the most important point though just to kind of keep hammering home as that short term changes and now the owl are not concerned for the vast majority of patients so when there's a short term change associate with induction i think that's not gonna be
spk_0: such an important consideration particularly if that short term excursion is associated with higher advocacy because of the the production and i g g the can be achieved with some induction with you know one
spk_1: got it thank you no from thank you ladies and gentlemen that includes our question and answer session not for back to doctors awesome and funny final comment
spk_20: i was a while i appreciate it when you're ready to call i'm sure you can really hear i do the as i'm based on a remarkable market opportunity fifteen an ounce indications across the classes is this is really really unique i think
spk_21: our do the admins also based on forty no one differentiated profile with abroad broad therapeutic window and a simple suffocate injection form factor
spk_0: and base now on a strong balance sheet enabling us to pursue an ambitious parallel development program
Disclaimer